Astellas is also filing the EMA appiication (SECOND HALF 2013) that may be the wild card, since the trial was conducted in Europe
I am really puzzled how negative the sentiment is.... while volume has picked up, it seems that the market is scared and has little faith in TIVO.... biotechs have been up and yet AVEO is stuck under $7.50. I imagine that with a positive ODAC review the stock will shoot up to $12-13....perhaps even $14? what is everyone else expecting with positive ODAC?
this should give us confidence that they are going some good progress, especially with biomarjkers and BATON studies for RCC and TNBC... google the following:
"Will biomarkers revolutionise treatment with tivozanib?" published by Pharma Strategy Blog on feb 25, 2013
thanks once again for you insight and into CLDX and you deatiled pespective about where we are heading and why.
I have seen some of you posts on LGND board. Are CLDX and LGND you top biotech picks? it seems that LGND will be steadily increasing revenues while mor eoand more of the partnered programs are marketed, Krypolis being one of the most promising ones.